This excerpt taken from the MBRX 10-K filed Mar 13, 2007.
11.4 Scientific Publications
Schering shall be free to publish scientific articles about the Licensed Compound or Products in scientific publications but Metabasis may only do so with the prior written consent of Schering. Schering will first provide Metabasis with a copy of the proposed publication for review and comment. Schering shall give due consideration to any reasonable comments by Metabasis relating to such proposed press release or other public disclosure. Notwithstanding the foregoing, Metabasis shall be free to publish scientific articles concerning the HepDirect Technology generally and concerning a compound which may become a Substituted Compound but only prior to its becoming a Substituted Compound, provided, however, that Schering is given thirty (30) days advanced written notice by Metabasis of any such proposed publication concerning the HepDirect Technology generally or concerning a compound which may become a Substituted Compound and provided further that (a) Schering may delay such publication for a reasonable period of time, not to exceed three (3) months, to allow for any Patent Rights to be filed; and (b) Schering may request that any Schering Confidential Information contained within such draft publication is removed.